Reata Pharmaceuticals Inc buy tamam
Summary
This prediction ended on 05.11.21 with a price of €86.50. With a performance of 263.45% the BUY prediction by tamam was a big success. tamam has 50% into this predictionReata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on identifying, developing, and commercializing novel therapeutics for patients with severe and life-threatening diseases. The company's primary business areas include drug discovery and development in fields such as cardiovascular, fibrotic, mitochondrial, and neurodegenerative diseases. With a strong emphasis on research and innovation, Reata Pharmaceuticals seeks to deliver cutting-edge treatments that address unmet medical needs, improve patient outcomes, and significantly impact the lives of those suffering from rare and debilitating conditions. As a publicly traded company, Reata Pharmaceuticals is listed on the NASDAQ stock exchange under the ticker symbol "RETA."
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Reata Pharmaceuticals Inc | - | - | - | - |
iShares Core DAX® | -3.429% | 3.133% | 15.455% | 14.827% |
iShares Nasdaq 100 | -6.121% | -1.433% | 16.794% | 27.167% |
iShares Nikkei 225® | -7.364% | 1.018% | 8.293% | -2.680% |
iShares S&P 500 | -4.366% | 0.247% | 18.541% | 32.687% |
Comments by tamam for this prediction
In the thread Reata Pharmaceuticals Inc diskutieren
The study met the primary endpoint of the change in the modified FA Rating Scale (mFARS) at week 48 versus placebo. The treatment effect was time-dependent with the most significant improvement observed after 48 weeks.
In the thread Trading Reata Pharmaceuticals Inc